Summary:
- Agenus, an immuno-oncology company based in Lexington, MA, has received an investment from Zynext Ventures.
- The company is focused on developing therapeutics for high-unmet need cancers, with a lead program comprising Botensilimab (BOT) and Balstilimab (BAL).
- The investment will be used to expand operations, accelerate development of the lead program, and explore new indications and treatment lines.
Article:
Agenus, a prominent immuno-oncology company headquartered in Lexington, MA, recently announced a significant investment from Zynext Ventures. While the exact amount of the deal remains undisclosed, this partnership marks a crucial step forward for Agenus in advancing their mission to develop innovative therapeutics for cancers with high unmet needs.
Led by CEO Dr. Garo Armen, Agenus is at the forefront of developing a groundbreaking lead program that includes Botensilimab (BOT) and Balstilimab (BAL). These therapeutics form part of a cutting-edge immunotherapy platform designed to enhance and prolong the immune system’s response against tumor cells. Through advanced clinical trials, BOT/BAL have shown promising results across a diverse range of cancer types, benefiting over 1,200 patients in both late-stage and neoadjuvant settings.
With the infusion of funds from Zynext Ventures, Agenus plans to ramp up its operations and research and development efforts. The primary focus will be on accelerating the development of the BOT/BAL program, as well as exploring new indications and treatment lines that address critical unmet needs in the oncology landscape.
This strategic investment not only propels Agenus towards its goal of revolutionizing cancer treatment but also underscores the company’s commitment to pushing boundaries and making a meaningful impact in the field of immuno-oncology. Stay tuned for more updates on Agenus as they continue to drive innovation and progress in the fight against cancer.
FinSMEs
03/06/2025
